CN110559248B - Skin-care matrix and preparation method and application thereof - Google Patents
Skin-care matrix and preparation method and application thereof Download PDFInfo
- Publication number
- CN110559248B CN110559248B CN201911033366.8A CN201911033366A CN110559248B CN 110559248 B CN110559248 B CN 110559248B CN 201911033366 A CN201911033366 A CN 201911033366A CN 110559248 B CN110559248 B CN 110559248B
- Authority
- CN
- China
- Prior art keywords
- skin care
- skin
- matrix
- mass
- care matrix
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000011159 matrix material Substances 0.000 title claims abstract description 41
- 238000002360 preparation method Methods 0.000 title claims abstract description 7
- BJRNKVDFDLYUGJ-RMPHRYRLSA-N hydroquinone O-beta-D-glucopyranoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-RMPHRYRLSA-N 0.000 claims abstract description 38
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims abstract description 25
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 23
- 229960000271 arbutin Drugs 0.000 claims abstract description 19
- BJRNKVDFDLYUGJ-UHFFFAOYSA-N p-hydroxyphenyl beta-D-alloside Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-UHFFFAOYSA-N 0.000 claims abstract description 19
- MLSJBGYKDYSOAE-DCWMUDTNSA-N L-Ascorbic acid-2-glucoside Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)=C1O MLSJBGYKDYSOAE-DCWMUDTNSA-N 0.000 claims abstract description 16
- 239000001140 aloe barbadensis leaf extract Substances 0.000 claims abstract description 16
- 229940067599 ascorbyl glucoside Drugs 0.000 claims abstract description 16
- 239000002994 raw material Substances 0.000 claims abstract description 15
- 239000001947 glycyrrhiza glabra rhizome/root Substances 0.000 claims abstract description 13
- LQPLDXQVILYOOL-UHFFFAOYSA-I pentasodium;2-[bis[2-[bis(carboxylatomethyl)amino]ethyl]amino]acetate Chemical compound [Na+].[Na+].[Na+].[Na+].[Na+].[O-]C(=O)CN(CC([O-])=O)CCN(CC(=O)[O-])CCN(CC([O-])=O)CC([O-])=O LQPLDXQVILYOOL-UHFFFAOYSA-I 0.000 claims abstract description 12
- 108010006161 conchiolin Proteins 0.000 claims abstract description 11
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical class CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 claims abstract description 10
- WCVRQHFDJLLWFE-UHFFFAOYSA-N pentane-1,2-diol Chemical compound CCCC(O)CO WCVRQHFDJLLWFE-UHFFFAOYSA-N 0.000 claims abstract description 9
- 229920002385 Sodium hyaluronate Polymers 0.000 claims abstract description 8
- DFPAKSUCGFBDDF-ZQBYOMGUSA-N [14c]-nicotinamide Chemical compound N[14C](=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-ZQBYOMGUSA-N 0.000 claims abstract description 8
- 229940010747 sodium hyaluronate Drugs 0.000 claims abstract description 8
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 claims abstract description 8
- CDQSJQSWAWPGKG-UHFFFAOYSA-N butane-1,1-diol Chemical compound CCCC(O)O CDQSJQSWAWPGKG-UHFFFAOYSA-N 0.000 claims abstract description 7
- ANZUDYZHSVGBRF-UHFFFAOYSA-N 3-ethylnonane-1,2,3-triol Chemical compound CCCCCCC(O)(CC)C(O)CO ANZUDYZHSVGBRF-UHFFFAOYSA-N 0.000 claims abstract description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 claims description 27
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 claims description 22
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 claims description 15
- QCDWFXQBSFUVSP-UHFFFAOYSA-N 2-phenoxyethanol Chemical compound OCCOC1=CC=CC=C1 QCDWFXQBSFUVSP-UHFFFAOYSA-N 0.000 claims description 11
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 claims description 11
- 229960005323 phenoxyethanol Drugs 0.000 claims description 11
- 229940032094 squalane Drugs 0.000 claims description 11
- 229960003966 nicotinamide Drugs 0.000 claims description 10
- 235000005152 nicotinamide Nutrition 0.000 claims description 10
- 239000011570 nicotinamide Substances 0.000 claims description 10
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 claims description 9
- KWIUHFFTVRNATP-UHFFFAOYSA-N Betaine Natural products C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 claims description 9
- KWIUHFFTVRNATP-UHFFFAOYSA-O N,N,N-trimethylglycinium Chemical compound C[N+](C)(C)CC(O)=O KWIUHFFTVRNATP-UHFFFAOYSA-O 0.000 claims description 9
- 229920002125 Sokalan® Polymers 0.000 claims description 9
- 229960003237 betaine Drugs 0.000 claims description 9
- 229960001631 carbomer Drugs 0.000 claims description 9
- 239000000230 xanthan gum Substances 0.000 claims description 9
- 229920001285 xanthan gum Polymers 0.000 claims description 9
- 229940082509 xanthan gum Drugs 0.000 claims description 9
- 235000010493 xanthan gum Nutrition 0.000 claims description 9
- -1 ascorbic acid glucoside Chemical class 0.000 claims description 8
- 235000011187 glycerol Nutrition 0.000 claims description 8
- NCZPCONIKBICGS-UHFFFAOYSA-N 3-(2-ethylhexoxy)propane-1,2-diol Chemical compound CCCCC(CC)COCC(O)CO NCZPCONIKBICGS-UHFFFAOYSA-N 0.000 claims description 6
- 229940069638 aloe vera leaf extract Drugs 0.000 claims description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 6
- 229940100524 ethylhexylglycerin Drugs 0.000 claims description 6
- 238000002156 mixing Methods 0.000 claims description 6
- 229940015975 1,2-hexanediol Drugs 0.000 claims description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 4
- 239000006071 cream Substances 0.000 claims description 4
- FHKSXSQHXQEMOK-UHFFFAOYSA-N hexane-1,2-diol Chemical compound CCCCC(O)CO FHKSXSQHXQEMOK-UHFFFAOYSA-N 0.000 claims description 4
- 238000003756 stirring Methods 0.000 claims description 3
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 claims description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Natural products OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 2
- BIVBRWYINDPWKA-VLQRKCJKSA-L Glycyrrhizinate dipotassium Chemical compound [K+].[K+].O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@H]1CC[C@]2(C)[C@H]3C(=O)C=C4[C@@H]5C[C@](C)(CC[C@@]5(CC[C@@]4(C)[C@]3(C)CC[C@H]2C1(C)C)C)C(O)=O)C([O-])=O)[C@@H]1O[C@H](C([O-])=O)[C@@H](O)[C@H](O)[C@H]1O BIVBRWYINDPWKA-VLQRKCJKSA-L 0.000 claims description 2
- 229960005070 ascorbic acid Drugs 0.000 claims description 2
- 235000010323 ascorbic acid Nutrition 0.000 claims description 2
- 239000011668 ascorbic acid Substances 0.000 claims description 2
- GPLRAVKSCUXZTP-UHFFFAOYSA-N diglycerol Chemical compound OCC(O)COCC(O)CO GPLRAVKSCUXZTP-UHFFFAOYSA-N 0.000 claims description 2
- 229940101029 dipotassium glycyrrhizinate Drugs 0.000 claims description 2
- SZXQTJUDPRGNJN-UHFFFAOYSA-N dipropylene glycol Chemical compound OCCCOCCCO SZXQTJUDPRGNJN-UHFFFAOYSA-N 0.000 claims description 2
- 229930182478 glucoside Natural products 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 239000008267 milk Substances 0.000 claims description 2
- 210000004080 milk Anatomy 0.000 claims description 2
- 235000013336 milk Nutrition 0.000 claims description 2
- 239000002884 skin cream Substances 0.000 claims description 2
- 239000011780 sodium chloride Substances 0.000 claims description 2
- 239000001509 sodium citrate Substances 0.000 claims description 2
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 claims description 2
- 239000004909 Moisturizer Substances 0.000 claims 1
- 230000001333 moisturizer Effects 0.000 claims 1
- 239000002537 cosmetic Substances 0.000 abstract description 11
- 230000003020 moisturizing effect Effects 0.000 abstract description 11
- 230000002087 whitening effect Effects 0.000 abstract description 10
- 210000003491 skin Anatomy 0.000 description 52
- 102000003425 Tyrosinase Human genes 0.000 description 16
- 108060008724 Tyrosinase Proteins 0.000 description 16
- 230000000052 comparative effect Effects 0.000 description 14
- 230000000694 effects Effects 0.000 description 11
- 230000005764 inhibitory process Effects 0.000 description 11
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 8
- MGJZITXUQXWAKY-UHFFFAOYSA-N diphenyl-(2,4,6-trinitrophenyl)iminoazanium Chemical compound [O-][N+](=O)C1=CC([N+](=O)[O-])=CC([N+]([O-])=O)=C1N=[N+](C=1C=CC=CC=1)C1=CC=CC=C1 MGJZITXUQXWAKY-UHFFFAOYSA-N 0.000 description 6
- HHEAADYXPMHMCT-UHFFFAOYSA-N dpph Chemical compound [O-][N+](=O)C1=CC([N+](=O)[O-])=CC([N+]([O-])=O)=C1[N]N(C=1C=CC=CC=1)C1=CC=CC=C1 HHEAADYXPMHMCT-UHFFFAOYSA-N 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 229940067082 pentetate Drugs 0.000 description 5
- QPCDCPDFJACHGM-UHFFFAOYSA-N N,N-bis{2-[bis(carboxymethyl)amino]ethyl}glycine Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(=O)O)CCN(CC(O)=O)CC(O)=O QPCDCPDFJACHGM-UHFFFAOYSA-N 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 230000002292 Radical scavenging effect Effects 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 150000003254 radicals Chemical class 0.000 description 3
- 238000010998 test method Methods 0.000 description 3
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
- 241000234435 Lilium Species 0.000 description 2
- 238000006555 catalytic reaction Methods 0.000 description 2
- 239000002131 composite material Substances 0.000 description 2
- 230000007760 free radical scavenging Effects 0.000 description 2
- 229920002674 hyaluronan Polymers 0.000 description 2
- 229960003160 hyaluronic acid Drugs 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000008099 melanin synthesis Effects 0.000 description 2
- 210000002780 melanosome Anatomy 0.000 description 2
- BDJRBEYXGGNYIS-UHFFFAOYSA-N nonanedioic acid Chemical compound OC(=O)CCCCCCCC(O)=O BDJRBEYXGGNYIS-UHFFFAOYSA-N 0.000 description 2
- 230000019612 pigmentation Effects 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 239000004166 Lanolin Substances 0.000 description 1
- 229930194248 Licoflavone Natural products 0.000 description 1
- MEHHCBRCXIDGKZ-UHFFFAOYSA-N Licoflavone C Natural products CC(C)=CCC1=C(O)C=C(O)C(C(C=2)=O)=C1OC=2C1=CC=C(O)C=C1 MEHHCBRCXIDGKZ-UHFFFAOYSA-N 0.000 description 1
- 102000004316 Oxidoreductases Human genes 0.000 description 1
- 108090000854 Oxidoreductases Proteins 0.000 description 1
- 206010057249 Phagocytosis Diseases 0.000 description 1
- 206010048245 Yellow skin Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- BJRNKVDFDLYUGJ-ZIQFBCGOSA-N alpha-Arbutin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-ZIQFBCGOSA-N 0.000 description 1
- 229940033280 alpha-arbutin Drugs 0.000 description 1
- 230000003266 anti-allergic effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 229960002255 azelaic acid Drugs 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000000536 complexating effect Effects 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 238000005562 fading Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- LBQIJVLKGVZRIW-ZDUSSCGKSA-N glabridin Chemical compound C1([C@H]2CC3=CC=C4OC(C=CC4=C3OC2)(C)C)=CC=C(O)C=C1O LBQIJVLKGVZRIW-ZDUSSCGKSA-N 0.000 description 1
- 229940093767 glabridin Drugs 0.000 description 1
- PMPYOYXFIHXBJI-ZDUSSCGKSA-N glabridin Natural products C1([C@H]2CC=3C=CC4=C(C=3OC2)CCC(O4)(C)C)=CC=C(O)C=C1O PMPYOYXFIHXBJI-ZDUSSCGKSA-N 0.000 description 1
- LBQIJVLKGVZRIW-UHFFFAOYSA-N glabridine Natural products C1OC2=C3C=CC(C)(C)OC3=CC=C2CC1C1=CC=C(O)C=C1O LBQIJVLKGVZRIW-UHFFFAOYSA-N 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 229940072008 glycyrrhiza glabra extract Drugs 0.000 description 1
- 239000001649 glycyrrhiza glabra l. absolute Substances 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 239000000543 intermediate Substances 0.000 description 1
- 210000002510 keratinocyte Anatomy 0.000 description 1
- 229940039717 lanolin Drugs 0.000 description 1
- 235000019388 lanolin Nutrition 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 229940051810 licorice root extract Drugs 0.000 description 1
- 235000020725 licorice root extract Nutrition 0.000 description 1
- 230000031700 light absorption Effects 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000004200 microcrystalline wax Substances 0.000 description 1
- 235000019808 microcrystalline wax Nutrition 0.000 description 1
- 229940114937 microcrystalline wax Drugs 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 229940069403 pentetate pentasodium Drugs 0.000 description 1
- 230000008782 phagocytosis Effects 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 239000002516 radical scavenger Substances 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000006965 reversible inhibition Effects 0.000 description 1
- 230000002000 scavenging effect Effects 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 229960004441 tyrosine Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/55—Phosphorus compounds
- A61K8/553—Phospholipids, e.g. lecithin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/60—Sugars; Derivatives thereof
- A61K8/602—Glycosides, e.g. rutin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/67—Vitamins
- A61K8/678—Tocopherol, i.e. vitamin E
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/73—Polysaccharides
- A61K8/735—Mucopolysaccharides, e.g. hyaluronic acid; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9794—Liliopsida [monocotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/02—Preparations for care of the skin for chemically bleaching or whitening the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/59—Mixtures
- A61K2800/592—Mixtures of compounds complementing their respective functions
- A61K2800/5922—At least two compounds being classified in the same subclass of A61K8/18
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/74—Biological properties of particular ingredients
- A61K2800/78—Enzyme modulators, e.g. Enzyme agonists
- A61K2800/782—Enzyme inhibitors; Enzyme antagonists
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Birds (AREA)
- Dermatology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Cosmetics (AREA)
Abstract
The invention belongs to the technical field of cosmetics, and particularly relates to a skin-care matrix and a preparation method and application thereof. The skin-care matrix is prepared from the following raw materials in percentage by mass: 1-3% of ascorbyl glucoside, 0.05-0.5% of aloe barbadensis leaf extract, 0.01-0.1% of glycyrrhiza glabra root extract, 0.5-1% of hydrolyzed conchiolin, 1-3% of arbutin, 0.5-1.5% of nicotinamide, 1-2% of sodium hyaluronate, 1-5% of hydrogenated lecithin, 0.05-1% of pentasodium pentetate, 2-5% of butanediol, 1-2% of glycerol, 0.5-1.5% of 1, 2-pentanediol, 2-3% of ethylhexylglycerol and the balance of water. The skin-care matrix disclosed by the invention is applied to skin-care products/cosmetics, and has stable and efficient whitening and moisturizing effects, so that the skin becomes good.
Description
Technical Field
The invention belongs to the technical field of cosmetics, and particularly relates to a skin-care matrix and a preparation method and application thereof.
Background
The skin, which is the surface of the human body in contact with the outside, plays a very important role in protecting and maintaining the normal circulatory metabolism and water balance in the body. Because the problems of dark yellow skin, pigmentation and the like occur due to the increase of work and living pressure and the fact that the natural environment is worse, whitening and moisturizing skin care products/cosmetics are favored by people, and various skin care products/cosmetics appear nowadays.
Chinese patent CN108113920A discloses a sustained-release whitening composite moisturizing cream matrix and a preparation method and application thereof, and specifically discloses a whitening composite moisturizing cream matrix which is composed of alpha-arbutin, nicotinamide, licoflavone, sodium hyaluronate, algal polysaccharide, polyquaternium-73, azelaic acid, lecithin, microcrystalline wax, lanolin alcohol, paraffin and water.
Chinese CN108066237A discloses a composition with whitening and spot-lightening effects, application thereof and a skin care product, and specifically discloses a composition comprising: 0.01-1% of hydrolyzed conchiolin and 0.01-3% of lily extract. In the composition, the hydrolyzed conchiolin and the lily extract are cooperatively matched, so that the obtained composition has the effects of remarkably whitening and fading spots, has anti-allergy and anti-inflammatory effects, and can effectively protect skin from damage and pigmentation caused by UVB irradiation.
At present, glabridin in glycyrrhiza glabra extract can inhibit tyrosinase activity competitively, but the price is high; although arbutin can inhibit the activity of tyrosinase in the skin, the effective dose is higher; although ascorbyl glucoside can prevent the oxidation process of melanin, remove oxygen free radicals, reduce melanin intermediates and melanin polymers to inhibit the production of melanin, it has reversible inhibition; although niacinamide inhibits the phagocytosis of melanosomes by keratinocytes, thereby inhibiting the transport of melanosomes, the impurity components contained in the raw material have a stimulating effect on the skin. Therefore, the functional components are more or less applied to skin care products/cosmetics, but how to determine the optimal proportion of the functional components to ensure that the synergistic effect between the functional components reaches the maximum value and the side effect is relatively small has great significance.
Disclosure of Invention
The skin-care matrix disclosed by the invention is applied to skin-care products/cosmetics, can keep the DPPH free radical clearance rate above 87% and the tyrosinase inhibition rate above 95%, and has the effects of stably and efficiently whitening and moisturizing.
In order to achieve the purpose, the invention adopts the following technical scheme:
a skin-care matrix is prepared from the following raw materials in percentage by mass: 1-3% of ascorbyl glucoside, 0.05-0.5% of aloe barbadensis leaf extract, 0.01-0.1% of glycyrrhiza glabra root extract, 0.5-1% of hydrolyzed conchiolin, 1-2% of arbutin, 0.5-1.5% of nicotinamide, 1-2% of sodium hyaluronate, 1-5% of hydrogenated lecithin, 0.05-1% of pentetate pentasodium, 2-5% of butanediol, 1-2% of glycerol, 0.5-1.5% of 1, 2-pentanediol, 2-3% of ethylhexyl glycerol and the balance of water.
The inventor finds that the glycyrrhiza glabra root extract, the ascorbyl glucoside, the arbutin and the nicotinamide can mutually act synergistically, wherein the preferable mass ratio is 1 (80-100): 60: (30-50); in addition, the inventor finds that the aloe vera leaf extract and pentasodium penta-pentetate can also achieve interaction for improving the moisturizing performance, wherein the optimal mass ratio is 1: (1.5-3.5).
The glycyrrhiza glabra root extract and the aloe barbadensis leaf extract are not particularly limited in the present invention, and commercially available products well known to those skilled in the art may be used.
Furthermore, the material is prepared from the following raw materials in percentage by mass: ascorbic acid glucoside 1.8%, aloe barbadensis leaf extract 0.1%, glycyrrhiza glabra root extract 0.02%, hydrolyzed conchiolin 0.5%, arbutin 1.2%, niacinamide 0.9%, sodium hyaluronate 1.2%, hydrogenated lecithin 3.5%, pentasodium pentetate 0.2%, butylene glycol 2%, glycerin 1%, 1, 2-pentanediol 0.75%, ethylhexylglycerin 2%, and balance water.
The invention provides a preparation method of the skin care matrix, which comprises the following steps:
s1) slowly and sequentially adding nicotinamide, arbutin and hyaluronic acid into water under stirring to be uniformly mixed to obtain phase A; mixing Glycyrrhrizae radix extract, butanediol, glycerol, 1, 2-pentanediol, and ethylhexylglycerin to obtain phase B;
s2) adding ascorbyl glucoside, aloe barbadensis leaf extract, hydrolyzed conchiolin, hydrogenated lecithin, phase B of step S1 and pentasodium pentetate to phase A of step S1 in sequence, mixing, and homogenizing under high pressure to obtain skin care matrix.
The invention provides an application of the skin care matrix in preparing skin care products/cosmetics.
Further, the mass percentage of the skin care matrix in the skin care product/cosmetic is 5-25%.
The invention provides skin lotion containing the skin care matrix, which comprises the following raw materials in percentage by mass: 5% of skin care matrix, 0.1-0.8% of squalane, 0.01-0.05% of phenoxyethanol, 0.01-0.5% of xanthan gum, 2-5% of dipropylene glycol, 2-5% of diglycerol, 1-2% of 1, 2-hexanediol, 0.05% of polysorbate-200.02, 0.3-0.5% of sodium chloride, 0.1-0.2% of citric acid, 0.1-0.2% of sodium citrate, 0.1-0.3% of bis-diethoxydiol cyclohexane 1, 4-dicarboxylic acid ester and the balance of water.
The invention provides a skin care milk containing the skin care matrix, which comprises the following raw materials in percentage by mass: 13% of skin care matrix, 0.2-2% of squalane, 0.02-0.035% of phenoxyethanol, 0.2-0.5% of betaine, 0.1-0.5% of carbomer, 0.1-0.2% of potassium hydroxide, 1-5% of xanthan gum, 0.01-1% of dipotassium glycyrrhizinate and the balance of water.
The invention provides a skin care essence containing the skin care matrix, which comprises the following raw materials in percentage by mass: 20% of skin care matrix, 2-6% of squalane, 0.01-0.1% of phenoxyethanol, 0.5-2% of betaine, 0.3-0.5% of carbomer, 0.1-0.2% of potassium hydroxide, 0.1-1% of xanthan gum and the balance of water.
The invention provides a skin cream containing the skin care matrix, which comprises the following raw materials in percentage by mass: the skin care cream comprises 25% of skin care matrix, 3-8% of squalane, 0.015-0.075% of phenoxyethanol, 1-3% of betaine, 0.1-0.3% of carbomer, 0.1-0.2% of potassium hydroxide, 1-2% of 1, 2-hexanediol and the balance of water.
Compared with the prior art, the invention has the following beneficial effects:
(1) the skin care matrix controls the mass ratio of the glycyrrhiza glabra root extract to the ascorbyl glucoside to the arbutin to the nicotinamide to be 1 (80-100): 60: (30-50), due to the synergistic effect of the glycyrrhiza glabra root extract, the ascorbyl glucoside, the arbutin and the nicotinamide, the prepared skin care product/cosmetic can keep stable DPPH free radical clearance rate and tyrosinase inhibition rate, has the effect of efficient whitening, is small in component dosage, and can reduce the cost of enterprises.
(2) The interaction between the aloe vera leaf extract and the pentasodium pentetate in the skin-care matrix can ensure that the prepared skin-care product/cosmetic has the long-acting moisturizing effect.
Detailed Description
The present invention will be described in further detail with reference to the following examples. It should not be understood that the scope of the above-described subject matter of the present invention is limited to the following examples.
Examples 1 to 3 skin-care bases
Table 1 examples 1-3 formulations of skin care bases
| Raw materials | Example 1 | Example 2 | Example 3 |
| Ascorbyl glucoside/%) | 2.7 | 2.4 | 1.8 |
| Aloe barbadensis leaf extract/%) | 0.075 | 0.1 | 0.1 |
| Glycyrrhiza glabra root extract/%) | 0.03 | 0.03 | 0.02 |
| Hydrolyzed conchiolin/% | 0.75 | 0.75 | 0.5 |
| Arbutin/% | 1.8 | 1.8 | 1.2 |
| Nicotinamide/%) | 1.5 | 0.9 | 0.9 |
| Sodium hyaluronate/%) | 1.5 | 1.2 | 1.2 |
| Hydrogenated lecithin/% | 2 | 2 | 3.5 |
| Pentasodium penta acid/%) | 0.15 | 0.2 | 0.2 |
| Butanediol/%) | 3 | 2.5 | 2 |
| Glycerol/%) | 2 | 1.5 | 1 |
| 1, 2-pentanediol/%) | 0.5 | 1 | 0.75 |
| Ethylhexylglycerin/%) | 2 | 2 | 2 |
| Water/%) | 81.995 | 83.62 | 84.83 |
Examples 1-3 methods of preparing a skin care matrix comprising the steps of:
s1) slowly and sequentially adding nicotinamide, arbutin and hyaluronic acid into water under stirring to be uniformly mixed to obtain phase A; mixing Glycyrrhrizae radix extract, butanediol, glycerol, 1, 2-pentanediol, and ethylhexylglycerin to obtain phase B;
s2) adding ascorbyl glucoside, aloe barbadensis leaf extract, hydrolyzed conchiolin, hydrogenated lecithin, phase B of step S1 and pentasodium pentetate to phase A of step S1 in sequence, mixing, and homogenizing under high pressure to obtain skin care matrix.
Comparative examples 1 to 8 skin-care base materials
Similar to example 3, except that: the mass ratio of glycyrrhiza glabra root extract, ascorbyl glucoside, arbutin and niacinamide was changed as shown in table 2, and other parameters were the same as in example 3.
TABLE 2 relationship of the ratios of Glycyrrhiza glabra root extract, ascorbyl glucoside, arbutin and niacinamide
Comparative example 9 skin Care matrix
Similar to example 3, except that: pentasodium pentetate was not added and other parameters were the same as in example 3.
Comparative example 10 skin Care matrix
Similar to example 3, except that: the aloe vera leaf extract was not added, and the other parameters were the same as in example 3.
Comparative example 11 skin matrix
Similar to example 3, except that: pentasodium pentetate and aloe vera leaf extract were not added, and other parameters were the same as in example 3.
Example 4 skin care essence
Example 1 skin care base 20%, squalane 3%, phenoxyethanol 0.05%, betaine 1%, carbomer 0.5%, potassium hydroxide 0.12%, xanthan gum 0.5% and balance water.
Example 5 skin care essence
Example 2 skin care base 20%, squalane 3%, phenoxyethanol 0.05%, betaine 1%, carbomer 0.5%, potassium hydroxide 0.12%, xanthan gum 0.5% and balance water.
Example 6 skin care essence
Example 3 skin care base 20%, squalane 3%, phenoxyethanol 0.05%, betaine 1%, carbomer 0.5%, potassium hydroxide 0.12%, xanthan gum 0.5% and balance water.
Comparative examples 12 to 22 and skin care essence
Similar to example 6, except that: the skin care base of example 3 was replaced with the skin care bases of comparative examples 1 to 11, respectively, and the other parameters were the same as in example 3.
Test one, clearance test
1.1 test methods: DPPH is a stable organic free radical with a maximum absorption peak at 517nm in the visible region, and in ethanol solution, each molecule of DPPH can generate a stable nitrogenous free radical with a typical purple color in solution, and when it reacts with a radical scavenger which provides 1 electron, a colorless product is generated, so that the typical purple color of the solution is lightened. The DPPH free radical scavenging rate of the test is measured by a DPPH method for scavenging organic free radicals.
1.2 test methods: tyrosinase participating in melanin synthesis belongs to oxidoreductase and is a main rate-limiting enzyme for melanin synthesis, the tyrosinase and a substrate L-tyrosine of the tyrosinase can perform catalytic reaction, after a reagent with tyrosinase activity inhibition effect is added into an experimental system, the catalytic reaction can be inhibited, and the inhibition rate of the reagent on the tyrosinase activity is evaluated by measuring the light absorption value at 475nm before and after the reagent is added.
Test results of tables 31.1 and 1.2
As can be seen from Table 3, the DPPH radical scavenging rate and the tyrosinase inhibition rate of examples 1 to 3 are not much different, which indicates that the effects of examples 1 to 3 are stable. Comparative example 12 the licorice root extract was added in a small amount to reduce both DPPH free radical scavenging and tyrosinase inhibition, comparative example 13 being within the scope of the invention and comparable to the data of example 3; comparative example 14, in which ascorbyl glucoside was added in a small amount, decreased both DPPH radical clearance and tyrosinase inhibition, and particularly decreased DPPH radical clearance by a large amount, whereas comparative example 15, in which ascorbyl glucoside was added in a large amount, did not increase DPPH radical clearance and tyrosinase inhibition. Comparative example 16 the addition amount of arbutin was small, and both the DPPH radical scavenging rate and the tyrosinase inhibition rate were decreased. In the comparative example 17, the addition amount of arbutin is more than that of arbutin, so that the DPPH free radical clearance rate can be improved, but the tyrosinase inhibition rate is reduced; comparative examples 18 and 19, more nicotinamide was added with water to reduce DPPH radical scavenging and tyrosinase inhibition.
Test two, skin whitening and moisturizing test
The test method comprises the following steps: in each example, 20 Asian female subjects with the average age of 30 years were selected, skin care essence was applied 60 minutes before each day, the skin was irradiated with sunlight (< 1MED)3 times a week and continuously used for 4 weeks, and then a moisture tester was used to test the change of the moisture content of the skin, and a spectrophotometer was used to test the change of the skin brightness (L value).
TABLE 4 test results of test two
As can be seen from table 4, the moisture content variation and skin brightness variation of the epidermis in examples 1 to 3 are increased compared to those before use, indicating that the skin care essence can play a role in whitening and moisturizing. Compared with example 6, the comparative example 20 has less increase of moisture content after the skin around without adding pentetate, which indicates that pentetate plays an interaction role in lasting moisturizing of skin moisture, the inventor guesses that pentetate has a complexing effect on the principle, and aloe barbadensis leaf extract can penetrate through a three-dimensional structure formed by pentetate, so that moisturizing can be prolonged.
The foregoing embodiments are merely illustrative of the principles and utilities of the present invention and are not intended to limit the invention. Any person skilled in the art can modify or change the above-mentioned embodiments without departing from the spirit and scope of the present invention. Accordingly, it is intended that all equivalent modifications or changes which can be made by those skilled in the art without departing from the spirit and technical spirit of the present invention be covered by the claims of the present invention.
Claims (9)
1. The skin-care matrix is characterized by being prepared from the following raw materials in percentage by mass: 1-3% of ascorbyl glucoside, 0.05-0.5% of aloe vera leaf extract, 0.01-0.1% of glycyrrhiza glabra root extract, 0.5-1% of hydrolyzed conchiolin, 1-3% of arbutin, 0.5-1.5% of nicotinamide, 1-2% of sodium hyaluronate, 1-5% of hydrogenated lecithin, 0.05-1% of pentasodium pentetate, 2-5% of butanediol, 1-2% of glycerol, 0.5-1.5% of 1, 2-pentanediol, 2-3% of ethylhexylglycerol and the balance of water;
the mass ratio of the glycyrrhiza glabra root extract to the ascorbyl glucoside to the arbutin to the nicotinamide is 1 (80-100): 60: (30-50); the mass ratio of the aloe vera leaf extract to the pentasodium pentetate is 1: (1.5-3.5).
2. The skin care matrix according to claim 1, characterized by being prepared from the following raw materials in percentage by mass: ascorbic acid glucoside 1.8%, aloe barbadensis leaf extract 0.1%, glycyrrhiza glabra root extract 0.02%, hydrolyzed conchiolin 0.5%, arbutin 1.2%, niacinamide 0.9%, sodium hyaluronate 1.2%, hydrogenated lecithin 3.5%, pentasodium pentetate 0.2%, butylene glycol 2%, glycerin 1%, 1, 2-pentanediol 0.75%, ethylhexylglycerin 2%, and balance water.
3. A method of making a skin care base according to any of claims 1 to 2 comprising the steps of:
s1) slowly and sequentially adding nicotinamide, arbutin and sodium hyaluronate into water under stirring to be uniformly mixed to obtain phase A; mixing Glycyrrhrizae radix extract, butanediol, glycerol, 1, 2-pentanediol, and ethylhexylglycerin to obtain phase B;
s2) adding ascorbyl glucoside, aloe barbadensis leaf extract, hydrolyzed conchiolin, hydrogenated lecithin, the phase B of the step S1 and pentasodium pentetate into the phase A of the step S1 in sequence, mixing, and homogenizing under high pressure to obtain the skin care matrix.
4. Use of a skin care base according to any one of claims 1 to 2 in the preparation of a skin care product.
5. The use according to claim 4, wherein the skin care matrix is 5-25% by mass of the skin care product.
6. The skin moisturizer containing the skin care matrix according to claims 1-2, which is characterized by comprising the following raw materials in percentage by mass: 5% of skin care matrix, 0.1-0.8% of squalane, 0.01-0.05% of phenoxyethanol, 0.01-0.5% of xanthan gum, 2-5% of dipropylene glycol, 2-5% of diglycerol, 1-2% of 1, 2-hexanediol, 0.05% of polysorbate-200.02, 0.3-0.5% of sodium chloride, 0.1-0.2% of citric acid, 0.1-0.2% of sodium citrate, 0.1-0.3% of bis-diethoxydiol cyclohexane 1, 4-dicarboxylic acid ester and the balance of water.
7. The skin care milk containing the skin care matrix according to claims 1-2 is characterized by comprising the following raw materials in percentage by mass: 13% of skin care matrix, 0.2-2% of squalane, 0.02-0.035% of phenoxyethanol, 0.2-0.5% of betaine, 0.1-0.5% of carbomer, 0.1-0.2% of potassium hydroxide, 1-5% of xanthan gum, 0.01-1% of dipotassium glycyrrhizinate and the balance of water.
8. The skin care essence containing the skin care matrix according to claims 1-2, characterized by comprising the following raw materials in percentage by mass: 20% of skin care matrix, 2-6% of squalane, 0.01-0.1% of phenoxyethanol, 0.5-2% of betaine, 0.3-0.5% of carbomer, 0.1-0.2% of potassium hydroxide, 0.1-1% of xanthan gum and the balance of water.
9. A skin cream containing the skin care matrix as claimed in claims 1-2, which is characterized by comprising the following raw materials in percentage by mass: the skin care cream comprises 25% of skin care matrix, 3-8% of squalane, 0.015-0.075% of phenoxyethanol, 1-3% of betaine, 0.1-0.3% of carbomer, 0.1-0.2% of potassium hydroxide, 1-2% of 1, 2-hexanediol and the balance of water.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201911033366.8A CN110559248B (en) | 2019-10-28 | 2019-10-28 | Skin-care matrix and preparation method and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201911033366.8A CN110559248B (en) | 2019-10-28 | 2019-10-28 | Skin-care matrix and preparation method and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN110559248A CN110559248A (en) | 2019-12-13 |
| CN110559248B true CN110559248B (en) | 2022-05-24 |
Family
ID=68786159
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201911033366.8A Active CN110559248B (en) | 2019-10-28 | 2019-10-28 | Skin-care matrix and preparation method and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN110559248B (en) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112370370B (en) * | 2020-11-19 | 2022-07-26 | 苏州禾研生物技术有限公司 | Composition of oxygen-sugar double antibody and application thereof and product of oxygen-sugar double antibody |
| CN115990118A (en) * | 2022-12-29 | 2023-04-21 | 广州梵之容化妆品有限公司 | A water-soluble glabridin composition with high penetration enhancement and its preparation method |
| CN118021649A (en) * | 2024-02-27 | 2024-05-14 | 上海家化联合股份有限公司 | Composition with antioxidation effect |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009046116A1 (en) * | 2007-10-01 | 2009-04-09 | Dennis Gross | Skin care products containing multiple enhancers |
| CN103385806B (en) * | 2013-08-08 | 2015-08-12 | 珀莱雅化妆品股份有限公司 | A kind of method suppressing skin-lightening cosmetic to turn yellow |
| CN105434233B (en) * | 2015-12-08 | 2017-03-22 | 广州市花安堂生物科技有限公司 | Keratin repair essence |
| CN106074271A (en) * | 2016-07-08 | 2016-11-09 | 珍尔姿（广州）化妆品有限公司 | A kind of have the sun-proof air cushion frost with spot-removal function |
| CN107412061B (en) * | 2017-08-09 | 2019-09-13 | 广东丸美生物技术股份有限公司 | Skin matrix, preparation method and applications and cosmetics and preparation method thereof |
-
2019
- 2019-10-28 CN CN201911033366.8A patent/CN110559248B/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CN110559248A (en) | 2019-12-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103284940B (en) | Saccharomycetes fermented traditional Chinese medicine composition, as well as preparation method and application thereof | |
| CN112618400A (en) | Composition for improving skin color and whitening cosmetic | |
| CN112494406A (en) | Whitening and freckle-removing cosmetic and preparation method thereof | |
| CN109453087B (en) | Whitening skin-penetrating lotion, preparation method thereof and whitening cosmetic additive | |
| CN109363998B (en) | Whitening cosmetic additive, whitening essence stock solution and preparation method thereof | |
| KR20190122269A (en) | Topical skin care formulations comprising plant extracts | |
| CN110559248B (en) | Skin-care matrix and preparation method and application thereof | |
| CN111297788A (en) | Whitening and spot-fading essence and preparation method thereof | |
| KR101663946B1 (en) | Cosmetic composition containing an ginsenoside Rg3 reinforced extract of fermentative Ginseng flower(Panax ginseng C. A. Meyer) by Aureobasidium pullulans | |
| CN111067835A (en) | Whitening composition for resisting skin saccharification reaction and preparation method thereof | |
| CN111686068A (en) | Anti-wrinkle skin-activating cream and preparation method thereof | |
| CN108451893B (en) | Toning lotion with long-acting moisturizing effect and preparation method thereof | |
| CN104027271A (en) | Emulsion and preparation method thereof | |
| KR20150100288A (en) | Cosmetic composition comprising the extract of crude drug fermentation using the black yeast | |
| CN113712874A (en) | Skin care product containing water-soluble silicon element and preparation method and application thereof | |
| CN109330954B (en) | Whitening skin brightening lotion, preparation method thereof and tyrosinase inhibitor | |
| KR101266528B1 (en) | Moisturizing and/or whitening cosmetic composition comprising polysaccharide extracted from Lentinus edodes mycelium culture product | |
| CN112603870A (en) | Multi-effect essence cream and preparation method thereof | |
| CN112294739A (en) | Multi-effect whitening composition and application thereof in moisturizer | |
| KR20210144725A (en) | Anti-aging, antioxidant, anti-inflammatory and whitening agents, and cosmetics | |
| KR101685579B1 (en) | Method for manufacturing skin-whitener composition containing Thuja orientalis and skin-whitener composition prepared therefrom | |
| CN115227620B (en) | Nourishing, moisturizing and skin brightening lotion and preparation method thereof | |
| CN111166707B (en) | Facial anti-aging repairing and nursing composition and preparation method and application thereof | |
| KR101587077B1 (en) | Composition containing fermentated opuntia humifusa showing biological activity of skin | |
| CN111329783A (en) | Composition for instantly brightening skin color and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |